Scholarlink

<p>To compare early intraocular pressure (IOP) dynamics after intravitreal aflibercept 8&#xa0;mg and 2&#xa0;mg injections in patients with neovascular age-related macular degeneration (nAMD). In this prospective observational study, patients were classified according to the injected dose, with 50 eyes in each group receiving aflibercept 8&#xa0;mg (0.07 mL) or 2&#xa0;mg (0.05 mL). IOP was measured before injection and at 0, 10, 20, 30, and 60&#xa0;min after injection using a rebound tonometer. Longitudinal IOP changes were analyzed using linear mixed-effects models (LMM). Cumulative IOP burden was quantified as the area under the curve (AUC) from 0 to 60&#xa0;min. Baseline IOP did not differ between the 8-mg and 2-mg groups. Immediately after injection, IOP increased significantly in both groups, with a greater elevation in the 8-mg group (56.1 ± 14.9 vs. 45.4 ± 13.5 mmHg; <i>P</i> &lt; 0.001). IOP declined progressively thereafter and approached baseline levels by 60&#xa0;min in both groups. LMM demonstrated a significant group × time interaction (<i>P</i> = 0.001). The cumulative IOP burden was greater in the 8-mg group than in the 2-mg group (1351.4 ± 349.4 vs. 1101.0 ± 246.7 mmHg·min; <i>P</i> &lt; 0.001). In regression analyses, post-injection regurgitation was strongly associated with lower peak IOP and reduced AUC. Intravitreal aflibercept 8&#xa0;mg was associated with greater early post-injection IOP elevation and a higher cumulative IOP burden compared with aflibercept 2&#xa0;mg in patients with nAMD. These findings characterize distinct early IOP dynamics associated with higher-dose aflibercept therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early intraocular pressure dynamics after intravitreal aflibercept 8 mg versus 2 mg

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月28日

查看全文
  • Jung-Tae Kim,
  • Ji-Ho Jun,
  • Han-Jun Chung,
  • Min-Woo Lee

摘要

To compare early intraocular pressure (IOP) dynamics after intravitreal aflibercept 8 mg and 2 mg injections in patients with neovascular age-related macular degeneration (nAMD). In this prospective observational study, patients were classified according to the injected dose, with 50 eyes in each group receiving aflibercept 8 mg (0.07 mL) or 2 mg (0.05 mL). IOP was measured before injection and at 0, 10, 20, 30, and 60 min after injection using a rebound tonometer. Longitudinal IOP changes were analyzed using linear mixed-effects models (LMM). Cumulative IOP burden was quantified as the area under the curve (AUC) from 0 to 60 min. Baseline IOP did not differ between the 8-mg and 2-mg groups. Immediately after injection, IOP increased significantly in both groups, with a greater elevation in the 8-mg group (56.1 ± 14.9 vs. 45.4 ± 13.5 mmHg; P < 0.001). IOP declined progressively thereafter and approached baseline levels by 60 min in both groups. LMM demonstrated a significant group × time interaction (P = 0.001). The cumulative IOP burden was greater in the 8-mg group than in the 2-mg group (1351.4 ± 349.4 vs. 1101.0 ± 246.7 mmHg·min; P < 0.001). In regression analyses, post-injection regurgitation was strongly associated with lower peak IOP and reduced AUC. Intravitreal aflibercept 8 mg was associated with greater early post-injection IOP elevation and a higher cumulative IOP burden compared with aflibercept 2 mg in patients with nAMD. These findings characterize distinct early IOP dynamics associated with higher-dose aflibercept therapy.